ONCOZEN’s Platform Technology
: Chaperone-Mediated Protein Degradation, CMPD

Targeted protein degradation (TPD) has emerged as a novel therapeutic method for small molecule drug development to address diseases such as cancer, driven by the aberrant expression of a disease-causing protein.

In the attractive modality of TPD, CMPD Technology is innovative, novel approach to TPD field. CMPD is a technology that utilizes the cellular degradation pathways (ubiquitin-proteasome system, UPS) and biological processes via Chaperone Complex. Chaperones mediates the proper folding, stability and/or activation states of their substrate proteins. Chaperones can also recognize misfolded proteins and direct them towards degradation by the UPS.The ability of chaperones to direct proteins towards the UPS is facilitated by their direct interaction with many different E3 ubiquitin ligases. In terms of the structure, OZ Degrader consist of one moiety which is recognized by Chaperone Complex. This moiety is then chemically covalently linked to a small molecule that recognizes the Target protein. The designed bifunctional molecule promote the interaction of target proteins with components of Chaperone Complex which can direct them toward cellular degradation pathways (UPS), thereby inducing the degradation of the Target protein.

By removing target proteins with different biological processes via Chaperone Complex from other modalities,
OZ Degrader can provide Multiple & Unique Advantages ;

Selectively and Efficiently Degrade and Remove Disease-causing Proteins

Available to Design an Expansive Pipeline

Targeted degradation of “Undruggable Disease-causing Protein”

Targeted degradation of “Substrate protein of Chaperone complex”

Diversity of target protein rather than existing modalities of TPD which has limiting scope required to develop the E3 Ligase toolbox

Superior to Existing therapy often resulting in Drug Resistance

Improved Safety due to the Selective targeting of tumors

Novel OZ DEGRADERs & Core Technology

We have our own chaperone binding molecule with novel structure including a variety of linkers in library and are conducting novel OZ Degraders research in accordance with new target protein study. On the basis of our accumulated technique, optimized drug design for OZ Degraders can be carried out and validated via Artificial Intelligence Technique and we have the ability to derive outstanding drug candidates by developing and verifying based on outcomes of study from our own Research Headquarters Team.

Customization with ONCOZEN’s Platform Technology

By using our platform technology, we can provide service and/or co-development to potential partners who wan to develop TPD drugs with their novel molecule in development for new target proteins that are causing cancer and other diseases with significant unmet medical needs.